H.C. Wainwright analyst Emily Bodnar downgraded Context Therapeutics to Neutral from Buy without a price target after the company said it is discontinuing development of its lead asset, Onaxr, and focusing resources on CTIM-76. The analyst views the news as disappointing given efficacy data in the OATH study "were encouraging." The firm says Context no longer has any clinical programs.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CNTX:
- Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
- Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
- Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
- Context Therapeutics highlights clinical responses from Phase 2 OATH trial
- Context Therapeutics Stock Soars on FDA Approval
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue